Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for systemic and cutaneous mastocytosis
ACTRN12613001096741Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of omalizumab in systemic mastocytosis (SM) and cutaneous mastocytosis (CM) (2 arms), sponsored by Novartis. Primary endpoint: Improvement in AFIRMM score. Started Nov 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
systemic mastocytosis (SM)cutaneous mastocytosis (CM)
Beyond the preview
Go deeper on ACTRN12613001096741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001096741.